By Lina carolina 
Research has shed light on how a new type of antibody treatment reactivates patients’ immune cells to fight ovarian cancer. This groundbreaking work, spearheaded by Professor Sophia Karagiannis’s group at King’s College London, promises to deepen our understanding of patient responses to this innovative therapeutic approach and potentially pave the way for more effective ovarian cancer treatments.
A Paradigm Shift in Immunotherapy for Ovarian Cancer
Immunotherapy, a revolutionary class of cancer treatments, leverages the body’s own immune system to identify and eliminate malignant cells. While a significant portion of current antibody-based cancer therapies utilize Immunoglobulin G (IgG) antibodies, their efficacy against ovarian cancer has remained a persistent challenge. This limitation has spurred the search for alternative antibody types with distinct immune-modulating capabilities.
King’s College London researchers are at the forefront of this endeavor, being the first globally to develop a treatment derived from Immunoglobulin E (IgE) antibodies. IgE, traditionally known for its pivotal roles in orchestrating immune responses during allergic reactions and combating parasitic infections, possesses unique properties that make it a compelling candidate for cancer therapy. Unlike IgG antibodies, which primarily engage immune cells circulating in the bloodstream, IgE antibodies exhibit a remarkable affinity for immune cells residing within tissues. This characteristic is particularly advantageous for targeting solid tumors, such as those found in ovarian cancer. The research team has dedicated considerable effort to harnessing these potent immune-boosting attributes of IgE against these complex malignancies.
The Mechanism of MOv18 IgE: A Unique Approach
The focus of this recent investigation was an IgE antibody known as MOv18. Researchers explored its capacity to stimulate immune cells in patients diagnosed with ovarian cancer and its influence on the tumor’s intricate microenvironment. The findings reveal that MOv18 IgE operates through a distinctive mechanism, effectively counteracting the immune suppression typically imposed by ovarian tumors. It achieves this by activating various immune cell populations to mount a targeted assault against the cancer.
The potential of MOv18 IgE has already been underscored by promising outcomes in a Phase Ia clinical trial. This trial was meticulously designed and managed by the King’s College London research team, in collaboration with the National Institute for Health and Care Research (NIHR) Guy’s and St Thomas’ Clinical Research Facility and Cancer Research UK’s Centre for Drug Development. In a notable instance, at low therapeutic doses, MOv18 IgE was observed to induce tumor shrinkage in an ovarian cancer patient who had shown no response to conventional treatments. The subsequent study aimed to elucidate the precise molecular and cellular mechanisms by which this antibody exerts its anti-cancer effects within the complex immunological landscape of ovarian cancer.
Unraveling the Biology: Macrophages and T Cell Activation
The multidisciplinary study, published in the esteemed journal Nature Communications, involved extensive collaboration between King’s College London, Guy’s and St Thomas’ NHS Foundation Trust, the Medical University of Vienna, Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, and SeromYx Systems, Inc. A key area of investigation was the interaction of MOv18 IgE with specific immune cell subsets within ovarian cancer patients, with a particular emphasis on macrophages.
Macrophages, typically functioning as crucial components of the innate immune system, are responsible for engulfing and neutralizing pathogens. However, in the context of cancer, these cells can be co-opted and corrupted by the tumor. This corruption leads to a suppression of their anti-cancer functions, with reprogrammed macrophages often actively promoting tumor growth and survival.
Previous preclinical research conducted in animal models had suggested that MOv18 IgE could effectively "re-educate" these compromised macrophages, redirecting them towards an anti-tumorigenic state. To validate these findings in a human setting, the King’s College London team first obtained macrophages from healthy donors. These cells were then exposed to cancerous fluid samples collected from the peritoneal cavity – the primary site for ovarian cancer metastasis – of patients diagnosed with the disease. In parallel, macrophages were directly isolated from these patient-derived cancerous fluid samples, ensuring a direct link to the human tumor microenvironment. All patient samples were ethically sourced and collected from Guy’s and St Thomas’ NHS Foundation Trust.
Across both experimental setups, a consistent observation was the suppression of immune activity in macrophages when exposed to the ovarian cancer milieu. Crucially, the researchers discovered that MOv18 IgE was capable of binding to and activating these suppressed macrophages. This activation empowered the macrophages to effectively kill ovarian cancer cells. Furthermore, through this potent activation, MOv18 IgE was found to reverse the immunosuppressive influence that ovarian cancer macrophages exert on other critical immune cells, namely T cells. T cells are widely recognized as central players in establishing and maintaining long-term immune surveillance and memory against cancer.
Dr. Gabriel Osborn, who led this research as a PhD student at King’s College London, elaborated on these pivotal findings: "We discovered that within patients, ovarian cancer fundamentally rewires macrophages, diverting them from their normal immune-activating roles. Instead, they forge an immunosuppressive alliance with T cells, creating a formidable barrier to anti-cancer immunity. MOv18 IgE, however, acts as a catalyst, prompting patient macrophages to not only eliminate cancer cells but also to undergo a highly inflammatory activation. This activation, in turn, dismantles the suppressive effects these macrophages had on T cells. This study provides vital patient-level data that corroborates our earlier laboratory observations for MOv18 IgE and, for the first time, demonstrates that IgE-driven macrophage stimulation can effectively activate the broader tumor immune system."
Clinical Corroboration and Future Directions
Building upon these laboratory-based revelations, the research team extended their analysis to tumor biopsies obtained from two patients who had participated in the MOv18 IgE Phase Ia clinical trial. Biopsies collected prior to treatment were compared with those obtained post-treatment. The analysis revealed a significant increase in the presence of both macrophages and T cells in the post-treatment samples. This observation strongly suggests that these two key immune cell populations play a crucial role in mediating the anti-tumor activity of MOv18 IgE.
Professor Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy at King’s College London and the senior author of the study, emphasized the importance of fundamental research in advancing clinical applications: "Understanding the underlying biology of how a treatment functions is absolutely paramount to accelerating its journey from the laboratory to patients. Our findings clearly demonstrate that immune cells, which are typically inhibited within the tumor’s ‘microenvironment,’ are effectively redirected by IgE to target cancer cells. While we are diligently progressing with further clinical testing in patients, it is imperative that we persist in our pursuit to comprehend precisely how MOv18 IgE, and a broader array of IgE-based antibodies we are currently investigating, harness the immune system across diverse patient groups and cancer types."
Dr. Debra Josephs, Consultant Medical Oncologist at Guy’s and St Thomas’ NHS Foundation Trust and a co-author of the study, who was instrumental in developing the preclinical research that guided MOv18 IgE into clinical trials, highlighted the continuous drive for discovery: "Our overarching goal is to deepen our understanding of the intricate relationship between the immune system and cancer, with the ultimate aim of identifying superior treatments for patients. During the preclinical development of MOv18 IgE, we established the critical role of activating and migrating tumor-associated macrophages into cancer lesions for this antibody treatment to be successful. This current research represents a significant stride forward in the development of MOv18 IgE by enhancing our comprehension of macrophage-mediated mechanisms, thereby bolstering the therapeutic potential of this novel antibody."
Professor James Spicer, Professor of Experimental Cancer Medicine at King’s College London, Consultant in Medical Oncology at Guy’s and St Thomas’ NHS Foundation Trust, and the Chief Clinical Investigator of the MOv18 IgE Phase Ia trial, also a co-author of the study, underscored the ongoing need for improved patient outcomes: "We are committed to achieving better results for our patients. Significant progress is being made through meticulous study of the immune system and the complex environment in which cancer thrives. In our ongoing research, we are actively striving to leverage the inherent power of IgE to develop novel and effective treatments that can complement the established IgG antibody drugs currently utilized in clinical practice."
Broader Implications and Future Prospects
The successful application of MOv18 IgE in ovarian cancer could have far-reaching implications for the treatment of other solid tumors where immune suppression is a significant hurdle. The ability of IgE to engage tissue-resident immune cells and reprogram immunosuppressive tumor microenvironments presents a compelling strategy for overcoming therapeutic resistance.
The research was generously supported by key funding bodies including Cancer Research UK, the Medical Research Council, and Breast Cancer Now. Further acknowledgments were extended to the Cancer Research UK City of London Centre and the King’s Health Partners Centre for Translational Medicine for their invaluable contributions.
As clinical trials continue to progress, the detailed understanding of MOv18 IgE’s mechanism of action, as elucidated by this study, will be crucial for optimizing treatment strategies, identifying patient populations most likely to benefit, and potentially developing combination therapies. This work represents a significant step forward in the quest to unlock the full potential of IgE-based immunotherapies in the fight against cancer. The ongoing research into a wider panel of IgE-based antibodies further suggests a promising future for this class of therapeutics in revolutionizing cancer treatment paradigms.